Want to see SE:ACOU full AI Analyst Report?

AcouSort AB (ACOU) Price & Analysis

0 Followers

ACOU Stock Chart & Stats

kr2.64

-kr3.18(-45.56%)

At close: Mar 06 4:00 PM EST

kr2.64

-kr3.18(-45.56%)

Day’s Range― - ―

52-Week Rangekr2.03 - kr5.16

Previous CloseN/A

Volume449.84K

Average Volume (3M)29.24K

Market Cap

kr75.98M

Enterprise Valuekr75.16M

Total Cash (Recent Filing)kr14.57M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.15

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding21,163,902

10 Day Avg. Volume27,764

30 Day Avg. Volume29,240

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)3.27

Price to Sales (P/S)7.79

P/FCF Ratio-3.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr10.70M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces solvency risk and gives management durable financial flexibility. Over the coming months this supports continued R&D or commercial investment without immediate interest burdens, and provides runway to execute strategy while external funding is arranged if needed.

Improving Revenue GrowthConsistent TTM top-line improvement signals increasing market traction for products and services. Sustained revenue growth strengthens the path to scale, helps absorb fixed costs, and is a prerequisite for eventual margin recovery if unit economics improve with higher volumes and tighter cost control.

Differentiated Core TechnologyProprietary acoustophoresis technology offers a structural competitive edge for gentle, label-free cell and particle sorting. This technical differentiation suits diagnostics and cell therapy workflows, supporting durable product-market fit and potential long-term integration into lab and clinical processes.

Bears Say

Negative Gross ProfitNegative gross profit indicates unit economics do not yet cover direct production costs, a foundational profitability issue. This undermines sustainable margin expansion and means scale alone may not fix profitability without product cost reductions or higher-margin offerings.

Negative Free Cash FlowSustained negative operating and free cash flow forces reliance on external funding, which can dilute shareholders or constrain investment. A sharp FCF decline reduces runway and increases execution risk for commercialization and scaling over the medium term unless cash generation reverses.

Eroding Equity & Poor ReturnsVery negative ROE and declining equity reflect capital destruction and persistent losses. This weakens the company's ability to self-finance growth, raises the probability of future equity raises, and may limit credibility with large customers or partners seeking financially stable suppliers.

ACOU FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was kr2.03 and its highest was kr5.16 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is kr75.98M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is Aug 26, 2026 which is in 34 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on May 27, 2026. The company reported -kr0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.112.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -kr0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.139%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in SE:ACOU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.